Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARO-flare trial of darolutamide-induced PSMA upregulation in hormone-sensitive prostate cancer
NL-OMON60337Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of darolutamide in prostate cancer (PCa) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Number of lesions, Size of lesions and 8 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON60337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60337.